Latest developments: Management and treatment of preeclampsia;État des connaissances : prise en charge thérapeutique de la prééclampsie

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 37, Issue 1, 2008, Pages 5-15

  Winer, N ^a   Tsasaris, V ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b CHU Cochin ^*  (France)

Author keywords

Antihypertensive drugs; Corticosteroids and conservative management; Magnesium sulfate; Management preeclampsia; Preeclampsia prevention treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CORTICOSTEROID DERIVATIVE; DIHYDRALAZINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; METHYLDOPA; NICARDIPINE; NIFEDIPINE; CORTICOSTEROID;

CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; ECLAMPSIA; FETUS LUNG MATURATION; FETUS MORTALITY; FRANCE; HELLP SYNDROME; HOSPITALIZATION; HUMAN; IRRITABILITY; KIDNEY DISEASE; LOW DRUG DOSE; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MORBIDITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PERINATAL MORTALITY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURITY; PROPHYLAXIS; PROTEINURIA; REVIEW; RISK MANAGEMENT; SOLUTIO PLACENTAE; TREATMENT PLANNING; FEMALE; GESTATIONAL AGE; PREGNANCY; RECURRENT DISEASE;

ADRENAL CORTEX HORMONES; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CALCIUM; CALCIUM CHANNEL BLOCKERS; FEMALE; FRANCE; GESTATIONAL AGE; HELLP SYNDROME; HOSPITALIZATION; HUMANS; MAGNESIUM SULFATE; PRE-ECLAMPSIA; PREGNANCY; RECURRENCE;

EID: 38849115159     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2007.09.008     Document Type: Review

References (92)

1. Pottecher, et al. Réanimation des formes graves de pré-éclampsie : conférence d'experts, Société française d'anesthésie et de réanimation, Société française de médecine périnatale, Société française de pédiatrie, Collège national des gynécologues obstétriciens français. J Gynecol Obstet Biol Reprod (Paris) 30 (2001) 121-132
2. Espinoza J., Romero R., Nien J.K., Gomez R., Kusanovic J.P., Goncalves L.F., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196 (2007) 326 e1-13
3. MacKay A.P., Berg C.J., and Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 97 (2001) 533-538
4. Rochat R.W., Koonin L.M., Atrash H.K., and Jewett J.F. The maternal mortality collaborative. Maternal mortality in the US: report from the the maternal collaborative. Obstet Gynecol 72 (1988) 91-97
5. Preeclampsia foundation: www.preeclampsia.org.
6. Sibai B.M., Ramadan M.K., Usta I., Salama M., Mercer B.M., and Friedman S.A. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169 (1993) 1000-1006
7. Sibai B.M., and Barton J.R. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 196 (2007) 514 e19
8. Meher S., and Duley L. Rest during pregnancy for preventing pre-eclampsia and its complications in women with normal blood pressure. Cochrane Database Syst Rev 19 (2006) CD005939
9. Khedun S.M., Moodley J., Naicker T., and Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther 74 (1997) 221-258
10. Haddad B., Beaufils M., and Bavoux F. Prise en charge de la prééclampsie EMC (elsevier SAS Paris). Gynecologie-Obstétrique (2006) 5-036-A20
11. Duley L., Henderson-Smart D.J., Knight M., and King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev (2004) CD004659
12. Desvaux D., and Haddad B. Prevention de la prééclampsie. Presse Med 32 (2003) 1559-1565
13. National high blood pressure education program working group on high blood pressure in pregnancy Report. Am J Obstet Gynecol 2000; 183: Suppl: S1-S22.
14. Helewa M., Heaman M., Robinson M.A., and Thompson L. Community-based home-care program for the management of pre-eclampsia: an alternative. CMAJ 149 (1993) 829-834
15. Levin A.C., Doering P.L., and Hatton R.C. Use of nifedipine in the hypertensive diseases of pregnancy. Ann Pharmacother 28 (1994) 1371-1378
16. Brown M.A., Buddle M.L., Farrell T., and Davis G.K. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 187 (2002) 1046-1050
17. von Dadelszen P., Ornstein M.P., Bull S.B., Logan A.G., Koren G., and Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355 (2000) 87-92
18. Nayler W.G., and Poole-Wilson P. Calcium antagonists: definition and mode of action. Basic Res Cardiol 76 (1981) 1-15
19. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynecol 100 (1993) 959-961
20. Waterman E.J., Magee L.A., Lim K.I., Skoll A., Rurak D., and von Dadelszen P. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy 23 (2004) 155-169
21. Jegasothy R., and Paranthaman S. Sublingual nifedipine compared with intravenous hydralazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. J Obstet Gynecol Res 22 (1996) 21-24
22. Smith P., Anthony J., and Johanson R. Nifedipine in pregnancy. Br J Obstet Gynecol 107 (2000) 299-307
23. Carbonne B., Jannet D., Touboul C., Khelifati Y., and Milliez J. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol 81 (1993) 908-914
24. Hanff L.M., Vulto A.G., Bartels P.A., Roofthooft D.W., Bijvank B.N., Steegers E.A., et al. Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients. J Hypertens 23 (2005) 2319-2326
25. Aya A.G., Mangin R., Hoffet M., and Eledjam J.J. Intravenous nicardipine for severe hypertension in pre-eclampsia - effects of an acute treatment on mother and foetus. Intensive Care Med 25 (1999) 1277-1281
26. Vermillion S.T., Scardo J.A., Newman R.B., and Chauhan S.P. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol 181 (1999) 858-861
27. Saotome T., Minoura S., Terashi K., Sato T., Echizen H., and Ishizaki T. Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. J Clin Pharmacol 33 (1993) 979-988
28. Belfort M.A., Anthony J., Saade G.R., Allen J.C., and For the nimodipine study group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 348 (2003) 304-311
29. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006;3:CD001449.
30. Friedman S.A., Schiff E., Kao L., and Sibai B.M. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 172 (1995) 1785-1792
31. Crowley P.A. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 173 (1995) 322-335
32. Bernstein I.M., Horbar J.D., Badger G.J., Ohlsson A., and Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford network. Am J Obstet Gynecol 182 (2000) 198-206
33. Sibai B.M. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 30 (2006) 16-19
34. Amorim M.M., Santos L.C., and Faundes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol 180 (1999) 1283-1288
35. Odendaal H.J., Pattinson R.C., Bam R., Grove D., and Kotze T.J. Aggressive or expectant management for patients with severe preeclampsia between 28 and 34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 76 (1990) 1070-1075
36. Sibai B.M., Mercer B.M., Schiff E., and Friedman S.A. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 171 (1994) 818-822
37. Schiff E., Friedman S.A., and Sibai B.M. Conservative management of severe preeclampsia remote from term. Obstet Gynecol 84 (1994) 626-630
38. Terrone D.A., Rinehart B.K., Kimmel E.S., May W.L., Larmon J.E., and Morrison J.C. A prospective, randomized, controlled trial of high and low maintenance doses of magnesium sulfate for acute tocolysis. Am J Obstet Gynecol 182 (2000) 1477-1482
39. Grimes D.A., and Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 108 (2006) 986-989
40. Altman D., Carroli G., Duley L., Farrell B., Moodley J., Neilson J., Smith D., and Magpie trial collaboration group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet 359 (2002) 1877-1890
41. Sibai B.M. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 105 (2005) 402-410
42. Chan M.T., Boet R., Ng S.C., Poon W.S., and Gin T. Magnesium sulfate for brain protection during temporary cerebral artery occlusion. Acta Neurochir Suppl 95 (2005) 107-111
43. Sameshima H., Ota A., and Ikenoue T. Pretreatment with magnesium sulfate protects against hypoxic-ischemic brain injury but postasphyxial treatment worsens brain damage in seven-day-old rats. Am J Obstet Gynecol 180 (1999) 725-730
44. Sibai B.M. Magnesium sulfate is the ideal anticonvulsant in prééclampsie-eclampsia. Am J Obstet Gynecol 162 (1990) 1141-1145
45. Villar J., Abalos E., Nardin J.M., Merialdi M., and Carroli G. Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol 24 (2004) 607-615
46. The eclampsia collaborative group. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet 1995; 345:1455-63.
47. Lucas M.J., LeVeno K.J., and Cunningham F.G. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 333 (1995) 201-205
48. Witlin A.G., Friedman S.A., and Sibai B.M. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 176 (1997) 623-627
49. Belfort M.A., Tooke-Miller C., Allen Jr. J.C., Dizon-Townson D., and Varner M.A. Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas. Hypertens Pregnancy 21 (2002) 185-197
50. Richards A., Stather-Dunn L., and Moodley J. Cardio-pulmonary arrest after the administration of magnesium sulfate. S Afr Med J 67 (1985) 145
51. The Magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. Magpie trial follow-up study collaborative group. BJOG. 2007; 114:300-9.
52. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99: 159-67.
53. Rozenberg P. Interêt du sulfate de magnesium dans la prise en charge de la prééclampsie. Gynecol Obstet Fertil 34 (2006) 54-59
54. Benedetti T.J., Kates R., and Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol 152 (1985) 330-334
55. Belfort M.A., Anthony J., and Kirshon B. Respiratory function in severe gestational proteinuric hypertension: the effects of rapid volume expansion and subsequent vasodilatation with verapamil. Br J Obstet Gynecol 98 (1991) 964-972
56. Hupuczi P., Sziller I., Hruby E., Rigo B., Szabo G., and Papp Z. The rate of maternal complications in 107 pregnancies complicated with HELLP syndrome. Orv Hetil 147 (2006) 1377-1385
57. Kirshon B., Moise Jr. K.J., Cotton D.B., Longmire S., Jones M., Tessem J., et al. Role of volume expansion in severe pre-eclampsia. Surg Gynecol Obstet 167 (1988) 367-371
58. Ganzevoort W., Rep A., Bonsel G.J., Fetter W.P., van Sonderen L., De Vries J.I., and Wolf H. PETRA investigators. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 112 (2005) 1358-1368
59. Visser W., and Wallenburg H.C. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynecol 102 (1995) 111-117
60. Withagen M.I., Wallenburg H.C., Steegers E.A., Hop W.C., and Visser W. Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. BJOG 112 (2005) 910-914
61. Sibai B.M., Caritis S.N., Thom E., Klebanoff M., McNellis D., Rocco L., et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 329 (1993) 1213-1218
62. Haddad B., Deis S., Goffinet F., Paniel B.J., Cabrol D., and Siba B.M. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 190 (2004) 1590-1595 discussion 1595-1597
63. Beaufils M., Uzan S., Donsimoni R., and Colau J.C. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1 (1985) 840-842
64. Wallenburg H.C., and Rotmans N. Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. Am J Obstet Gynecol 157 (1987) 1230-1235
65. Trudinger B.J., Cook C.M., Thompson R.S., Giles W.B., and Connelly A. Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. Am J Obstet Gynecol 159 (1988) 681-685
66. Benigni A., Gregorini G., Frusca T., Chiabrando C., Ballerini S., Valcamonico A., et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 321 (1989) 357-362
67. Imperiale T.F., and Petrulis A.S. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 266 (1991) 260-264
68. Uzan S., Beaufils M., Breart G., Bazin B., Capitant C., and Paris J. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 337 (1991) 1427-1431
69. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative low-dose aspirin study in pregnancy) collaborative group. Lancet. 1994; 343:619-29.
70. Caritis S., Sibai B., Hauth J., Lindheimer M.D., Klebanoff M., Thom E., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 338 (1998) 701-705
71. Golding J. A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica low dose aspirin study group. Br J Obstet Gynecol 105 (1998) 293-299
72. Rotchell Y.E., Cruickshank J.K., Gay M.P., Griffiths J., Stewart A., Farrell B., et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynecol 105 (1998) 286-292
73. Subtil D., Goeusse P., Puech F., et al. Aspirin (100 mg) used for prevention of preeclampsia in nulliparous women: The essai regional aspirin mere enfant study (part 1). Br J Obstet Gynecol 110 (2003) 475-484
74. Knight M, Duley L, Henderson-Smart D, King J. Antiplatelet agents for preventing and treating pre-eclampsia. In: Cochrane Collaboration: Cochrane Library. Issue 3. Oxford: Update Software, 2000.
75. Duley L., Henderson-Smart D., Knight M., and King J. Antiplatelet drugs for prevention of preeclampsia and its consequences: systematic review. Br Med J 322 (2001) 329-333
76. L Duley, DJ Henderson-Smart, M Knight, JF King Antiplatelet agents for preventing pre-eclampsia and its complications Cochrane Database Syst Rev 2006 Issue.
77. Askie L.M., Duley L., Henderson-Smart D.J., and Stewart L.A. PARIS collaborative group antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369 (2007) 1791-1798
78. Taufield P.A., Ales K.L., Resnick L.M., Druzin M.L., Gertner J.M., and Laragh J.H. Hypocalciuria in preeclampsia. N Engl J Med 316 (1987) 715-718
79. Belizan J.M., Villar J., Pineda O., Gonzalez A.E., Sainz E., Garrera G., et al. Reduction of blood pressure with calcium supplementation in young adults. JAMA 249 (1983) 1161-1165
80. Levine R.J., Hauth J.C., Curet L.B., Sibai B.M., Catalano P.M., Morris C.D., et al. Trial of calcium to prevent preeclampsia. N Engl J Med 337 (1997) 69-76
81. Villar J., Abdel-Aleem H., Merialdi M., Mathai M., Ali M.M., Zavaleta N., et al., World Health Organization Calcium Supplementation for the Prevention of Preeclampsia Trial Group. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 194 (2006) 639-649
82. Hofmeyr G.J., Atallah A.N., and Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 3 (2006) CD001059
83. Poston L., and Chappell LC. Is oxidative stress involved in the aetiology of pre-eclampsia?. Acta Paediatr Suppl 90 (2001) 3-5
84. Bayhan G., Kocyigit Y., Atamer A., Atamer Y., and Akkus Z. Potential atherogenic roles of lipids, lipoprotein A and lipid peroxidation in preeclampsia. Gynecol Endocrinol 21 (2005) 1-6
85. Chappell L.C., Seed P.T., Briley A.L., Kelly F.J., Lee R., Hunt B.J., et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 354 (1999) 810-816
86. Rumbold A.R., Crowther C.A., Haslam R.R., Dekker G.A., Robinson J.S., and ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 354 (2006) 1796-1806
87. Poston L., Briley A.L., Seed P.T., Kelly F.J., and Shennan A.H. Vitamins in pre-eclampsia (VIP) trial consortium. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367 (2006) 1145-1154
88. Spinnato J.A. New therapies in the prevention of preeclampsia. Curr Opin Obstet Gynecol 18 (2006) 601-604
89. Makrides M., Duley L., and Olsen S.F. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev 3 (2006) CD003402
90. Petri M., and Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 32 (2006) 591-607
91. Kupferminc M.J., Fait G., Many A., et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 20 (2001) 35-44
92. Mello G., Parretti E., Fatini C., et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 45 (2005) 86-91